FindTrial
Sign In

A placebo controlled, randomized study to examine the impact of 24-week orlistat treatment on postprandial triglyceridaemia, steatohepatitis and cardiovascular risk factors in overweight Chinese patie

A placebo controlled, randomized study to examine the impact of 24-week orlistat treatment on postprandial triglyceridaemia, steatohepatitis and cardiovascular risk factors in overweight Chinese patie

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-09000655
Enrollment
Unknown
Registered
2005-09-12
Start date
2004-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Interventions

Two groups:Orlistat 24 weeks versus Placebo

Sponsors

Roche
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 78 Years

Inclusion criteria

Inclusion criteria: Chinese patients with obesity and dyslipidaemia

Exclusion criteria

Exclusion criteria: Patients on orlistat within one month prior to study

Design outcomes

Primary

MeasureTime frame
Postprandial triglyceridaemia, visceral and hepatic fat deposition;—

Secondary

MeasureTime frame
Body weight, cardiovascular risk profiles;—

Countries

China

Contacts

Public ContactBrian Tomlinson
www.na@163.com852

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026